Johannes Voigt - Concepedia

Author

Johannes Voigt

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

J Voigt, J. H. VOIGT, J. VOIGT, J. Voigt, Johannes H Voigt, Johannes H. Voigt, Johannes Voigt, Voigt, Johannes

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)National Cancer Institute National Institutes of Health Georgetown University Center for Cancer Research

About

Johannes Voigt is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, biochemistry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	28	1.8K
2	Natural Sciences	19	25	1.4K
3	Engineering	8	8	317
4	Public Health	1	1	13
5	Social Sciences	1	1	98

Johannes Voigt

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Comparison of the NCI Open Database with Seven Large Chemical Structural Databases Johannes Voigt, Bruno Bienfait, Shaomeng Wang, Journal of Chemical Information and Computer Sciences Bioorganic ChemistryDatabasesMolecular BiologyOrganic ChemistryLarge Chemical Databases	2001	217
Discovery of Novel Chemotypes to a G-Protein-Coupled Receptor through Ligand-Steered Homology Modeling and Structure-Based Virtual Screening Claudio N. Cavasotto, Andrew Orry, Nicholas Murgolo, Journal of Medicinal Chemistry Drug TargetG-protein-coupled ReceptorMolecular BiologyNovel ChemotypesMedicinal Chemistry	2008	169
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill, Journal of Medicinal Chemistry Neurochemical BiomarkersPeptide ScienceEnzyme 1Chemical BiologyAlzheimer ’	2016	161
Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor Jared N. Cumming, Elizabeth M. Smith, Lingyan Wang, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetActive Bace1 InhibitorBiochemistryDrug Design	2012	151
Discovery of Cyclic Acylguanidines as Highly Potent and Selective β-Site Amyloid Cleaving Enzyme (BACE) Inhibitors: Part I—Inhibitor Design and Validation Zhaoning Zhu, Z. J. Sun, Yuanzan Ye, Journal of Medicinal Chemistry	2009	120
Enhanced CACTVS Browser of the Open NCI Database Wolf‐Dietrich Ihlenfeldt, Johannes Voigt, Bruno Bienfait, Journal of Chemical Information and Computer Sciences Open Nci DatabaseEngineeringHit IdentificationGraphical User InterfaceData Repository	2002	106
Comparison of Random Forest and Pipeline Pilot Naïve Bayes in Prospective QSAR Predictions Bin Chen, Robert P. Sheridan, Viktor Horn̆ák, Journal of Chemical Information and Modeling EngineeringMachine LearningMachine Learning ToolProspective Qsar PredictionsData Science	2012	103
Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical Library Design to Identify Novel μM Leads for the Development of nM BACE-1 (β-Site APP Cleaving Enzyme 1) Inhibitors Yu‐Sen Wang, Corey Strickland, Johannes Voigt, Journal of Medicinal Chemistry	2009	101
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction Andrew W. Stamford, Jack D. Scott, Sarah W. Li, ACS Medicinal Chemistry Letters Drug TargetNeurochemical BiomarkersPeptide ScienceSynaptic SignalingPharmaceutical Chemistry	2012	98
Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity Lan Hong, Cliff C. Cheng, Timothy J. Kowalski, Journal of Lipid Research	2011	85

Page 1